Pralnacasan (vertex pharmaceuticals).
Vertex is collaborating with Aventis Pharma AG (formerly Hoechst Marion Roussel Inc) in the development of pralnacasan, an interleukin (IL)-1b converting enzyme (ICE) inhibitor, for the potential treatment of inflammatory diseases [170247], [188293], [453094].
Siegmund
Britta
B
Universitatsklinikum Benjamin Franklin, Medizinische Klinik I, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. britta.siegmund@medizin.fu-berlin.de
Zeitz
Martin
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001381:Azepines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D061945:Caspase Inhibitors; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007546:Isoquinolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011724:Pyridazines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001381:Azepines; D061945:Caspase Inhibitors; D007546:Isoquinolines; D011480:Protease Inhibitors; D011724:Pyridazines; C476331:pralnacasan